Literature DB >> 15897250

The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites.

Susan Pratt1, Robert L Shepard, Ramani A Kandasamy, Paul A Johnston, William Perry, Anne H Dantzig.   

Abstract

5'-Fluorouracil (5-FU), used in the treatment of colon and breast cancers, is converted intracellularly to 5'-fluoro-2'-deoxyuridine (5-FUdR) by thymidine phosphorylase and is subsequently phosphorylated by thymidine kinase to 5'-fluoro-2'-dUMP (5-FdUMP). This active metabolite, along with the reduced folate cofactor, 5,10-methylenetetrahydrofolate, forms a stable inhibitory complex with thymidylate synthase that blocks cellular growth. The present study shows that the ATP-dependent multidrug resistance protein-5 (MRP5, ABCC5) confers resistance to 5-FU by transporting the monophosphate metabolites. MRP5- and vector-transfected human embryonic kidney (HEK) cells were employed in these studies. In 3-day cytotoxicity assays, MRP5-transfected cells were approximately 9-fold resistant to 5-FU and 6-thioguanine. Studies with inside-out membrane vesicles prepared from transfected cells showed that MRP5 mediates ATP-dependent transport of 5 micromol/L [(3)H]5-FdUMP, [(3)H]5-FUMP, [(3)H]dUMP, and not [(3)H]5-FUdR, or [(3)H]5-FU. The ATP-dependent transport of 5-FdUMP showed saturation with increasing concentrations and had a K(m) of 1.1 mmol/L and V(max) of 439 pmol/min/mg protein. Uptake of 250 micromol/L 5-FdUMP was inhibited by dUMP, cyclic nucleotide, cyclic guanosine 3',5'-monophosphate, amphiphilic anions such as probenecid, MK571, the phosphodiesterase inhibitors, trequinsin, zaprinast, and sildenafil, and by the chloride channel blockers, 5-nitro-2-(3-phenylpropylamino)-benzoic acid and glybenclamide. Furthermore, the 5-FU drug sensitivity of HEK-MRP5 cells was partially modulated to that of the HEK-vector by the presence of 40 micromol/L 5-nitro-2-(3-phenylpropylamino)-benzoic acid but not by 2 mmol/L probenecid. Thus, MRP5 transports the monophosphorylated metabolite of this nucleoside and when MRP5 is overexpressed in colorectal and breast tumors, it may contribute to 5-FU drug resistance.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15897250     DOI: 10.1158/1535-7163.MCT-04-0291

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  69 in total

Review 1.  ABC transporters and their role in nucleoside and nucleotide drug resistance.

Authors:  Yu Fukuda; John D Schuetz
Journal:  Biochem Pharmacol       Date:  2012-01-20       Impact factor: 5.858

2.  Pharmacogenetics of ABCB5, ABCC5 and RLIP76 and doxorubicin pharmacokinetics in Asian breast cancer patients.

Authors:  S Lal; N Sutiman; L L Ooi; Z W Wong; N S Wong; P C S Ang; B Chowbay
Journal:  Pharmacogenomics J       Date:  2016-03-15       Impact factor: 3.550

3.  Antiproliferative efficacies but minor drug transporter inducing effects of paclitaxel, cisplatin, or 5-fluorouracil in a murine xenograft model for head and neck squamous cell carcinoma.

Authors:  Dirk Theile; Zoltan Gal; Rolf Warta; Juan Pablo Rigalli; Bernd Lahrmann; Niels Grabe; Christel Herold-Mende; Gerhard Dyckhoff; Johanna Weiss
Journal:  Cancer Biol Ther       Date:  2014-01-21       Impact factor: 4.742

4.  ABCC5 is required for cAMP-mediated hindgut invagination in sea urchin embryos.

Authors:  Lauren E Shipp; Rose Z Hill; Gary W Moy; Tufan Gökırmak; Amro Hamdoun
Journal:  Development       Date:  2015-09-22       Impact factor: 6.868

5.  Role of the OATP Transporter Family and a Benzbromarone-SensitiveEfflux Transporter in the Hepatocellular Disposition of Vincristine.

Authors:  Johan Nicolaï; Louise Thevelin; Qi Bing; Bruno Stieger; Hugues Chanteux; Patrick Augustijns; Pieter Annaert
Journal:  Pharm Res       Date:  2017-08-21       Impact factor: 4.200

Review 6.  Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases.

Authors:  Zhe-Sheng Chen; Amit K Tiwari
Journal:  FEBS J       Date:  2011-08-01       Impact factor: 5.542

Review 7.  Multidrug resistance-associated proteins 3, 4, and 5.

Authors:  Piet Borst; Cornelia de Wolf; Koen van de Wetering
Journal:  Pflugers Arch       Date:  2006-04-04       Impact factor: 3.657

8.  Effluxing ABC transporters in human corneal epithelium.

Authors:  Kati-Sisko Vellonen; Eliisa Mannermaa; Helen Turner; Marika Häkli; J Mario Wolosin; Timo Tervo; Paavo Honkakoski; Arto Urtti
Journal:  J Pharm Sci       Date:  2010-02       Impact factor: 3.534

Review 9.  Combating Drug Resistance in Colorectal Cancer Using Herbal Medicines.

Authors:  Ga-Young Lee; Jin-Seok Lee; Chang-Gue Son; Nam-Hun Lee
Journal:  Chin J Integr Med       Date:  2020-08-01       Impact factor: 1.978

10.  STI571 sensitizes breast cancer cells to 5-fluorouracil, cisplatin and camptothecin in a cell type-specific manner.

Authors:  Jonathan T Sims; Sourik Ganguly; Leann S Fiore; Chris J Holler; Eun-Sil Park; Rina Plattner
Journal:  Biochem Pharmacol       Date:  2009-04-14       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.